Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

  • Exchange: Frankfurt
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Biotech

Rigel Pharmaceuticals Inc

+ Add to Watchlist

RI2A:GR

3.999 EUR 0.050 1.27%

As of 02:07:09 ET on 05/05/2015.

Snapshot for Rigel Pharmaceuticals Inc (RI2A)

Open: 4.000 Day's Range: 3.999 - 4.000 Volume: 203
Previous Close: 3.949 52wk Range: 1.269 - 4.515 1-Yr Rtn: +81.86%

Stock Chart for RI2A

No chart data available.
  • RI2A:GR 3.999
  • 1D
  • 1M
  • 1Y
3.949
Interactive RI2A Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for RI2A

Current P/E Ratio (ttm) -
Estimated P/E(12/2015) -
Relative P/E vs. DAX -
Earnings Per Share (USD) (ttm) -
Est. EPS (USD) (12/2015) -0.7620
Est. PEG Ratio -
Market Cap (M EUR) 352.11
Shares Outstanding (M) 88.05
30 Day Average Volume 420
Price/Book (mrq) -
Price/Sale (ttm) -
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 05/07/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for RI2A

  • Revenue
  • Net Income (M/USD)
  • Profit Margin (%)

Company Profile & Key Executives for RI2A

Rigel Pharmaceuticals, Inc. is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory and autoimmune diseases, as well as muscle disorders. The Company's research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms.

Raul R RodriguezChief Executive OfficerRyan D MaynardExec VP/CFO
Elliott B GrossbardExec VP/Chief Medical OfficerDonald G PayanExec VP/Pres:Discovery
More Company Profile & Key Executives for RI2A

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil